Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
Resource Type
Article
Authors
Song, Yuqin ; Malpica, Luis ; Cai, Qingqing ; Zhao, Weili ; Zhou, Keshu ; Wu, Jianqiu ; Zhang, Huilai ; Mehta-Shah, Neha ; Ding, Kaiyang ; Liu, Yao ; Li, Zengjun ; Zhang, Liling ; Zheng, Meifang ; Jin, Jie ; Yang, Haiyan ; Shuang, Yuerong ; Yoon, Dok Hyun ; Gao, Sujun ; Li, Wenyu ; Zhai, Zhimin ; Zou, Liqun ; Xi, Yaming ; Koh, Youngil ; Li, Fei ; Prince, Miles ; Zhou, Hui ; Lin, Lie ; Liu, Hui ; Allen, Pamela ; Roncolato, Fernando ; Yang, Zhenfan ; Kim, Won-Seog ; Zhu, Jun
Source
In The Lancet Oncology January 2024 25(1):117-125
Subject
Primary Research Articles
Language
ISSN
1470-2045